{"ModuleTitle": "Company Description", "CompanyName": "Retrophin, Inc.", "Symbol": "RTRX", "Address": "3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO, California, 92130, United States of America", "Phone": "760-260-8600", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Those statements in the following discussion that are not historical in nature\r\nshould be considered forward-looking statements that are inherently uncertain.\r\nActual results and the timing of the events may differ materially from those\r\ncontained in these forward-looking statements due to a number of factors,\r\nincluding those discussed in the \"Cautionary Statement Regarding Forward-Looking\r\nStatements\" and \"Risk Factors\" set forth elsewhere in this Annual Report.\r\nOverview\r\nWe are a biopharmaceutical company headquartered in San Diego, California,\r\nfocused on identifying, developing and delivering life-changing therapies to\r\npeople living with rare diseases. Our approach centers on our pipeline with\r\nmultiple late clinical-stage programs targeting rare diseases with significant\r\nunmet medical needs. Our research and development efforts are partially\r\nsupported by revenues from our commercialized products, Chenodal\u00ae, Cholbam\u00ae,\r\nThiola\u00ae and Thiola EC\u00ae.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f24%2f0001438533-20-000004.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Eric Dube", "title": "President, Chief Executive Officer & Director"}, {"name": "Laura M. Clague", "title": "Chief Financial & Accounting Officer"}, {"name": "Noah L. Rosenberg", "title": "Chief Medical Officer"}, {"name": "William E. Rote", "title": "Senior VP, Head-Research & Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}